A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial

Applied Longitudinal Analysis

2011 • 4,411 citations

Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents

1998 • 4,297 citations

1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults

1993 • 3,829 citations

UPDATE ON DRUG RESISTANCE MUTATIONS IN HIV-1

2001 • 1,694 citations

Applied longitudinal analysis

2004 • 1,352 citations

Surveillance for dracunculiasis, 1981-1991.

1992 • 1,112 citations

Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults

1999 • 1,008 citations

Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection

2002 • 647 citations

Comparison of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection

2003 • 355 citations

Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes

2004 • 305 citations

Use of Changes in Plasma Levels of Human Immunodeficiency Virus Type 1 RNA to Assess the Clinical Benefit of Antiretroviral Therapy

1998 • 249 citations

Update of the Drug Resistance Mutations in HIV-1: 2005.

2005 • 195 citations

A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients

2003 • 175 citations

A Randomized Clinical Trial Comparing Nelfinavir Or Nevirapine Associated to Zidovudine/Lamivudine in HIV-Infected Naive Patients (The Combine Study)

2002 • 137 citations

Decreased HIV-Associated T Cell Apoptosis by HIV Protease Inhibitors

2000 • 93 citations

Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial

2006 • 82 citations

Update of the drug resistance mutations in HIV-1: 2004.

2004 • 81 citations

Effect of Persistent Moderate Viremia on Disease Progression During HIV Therapy

2004 • 70 citations

Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen.

2005 • 61 citations

Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy The Swiss HIV Cohort Study

2001 • 49 citations

Differences in Cellular Activation and Apoptosis in HIV-Infected Patients Receiving Protease Inhibitors or Nonnucleoside Reverse Transcriptase Inhibitors

2002 • 41 citations

The Rationale and Design of the CPCRA (Terry Beirn Community Programs for Clinical Research on AIDS) 058 FIRST (Flexible Initial Retrovirus Suppressive Therapies) Trial

2001 • 37 citations

Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER Cohort

2005 • 33 citations

Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression

2004 • 32 citations

Comparison of Prognostic Importance of Latest CD4+ Cell Count and HIV RNA Levels in Patients with Advanced HIV Infection on Highly Active Antiretroviral Therapy

2005 • 23 citations

Efficacy and Safety of Abacavir Plus Lamivudine Versus Didanosine Plus Stavudine When Combined with a Protease Inhibitor, a Nonnucleoside Reverse Transcriptase Inhibitor, or Both in HIV-1 Positive Antiretroviral-Naive Persons

2004 • 11 citations

Deleted Work

1955 • 0 citations